Conexeu Sciences has produced the first 3D-printed collagen-based extracellular matrix using its CXU platform, signaling a potential shift in regenerative medicine.
Conexeu Sciences has produced what it says is the first 3D-printed structure made entirely from a functional collagen-based extracellular matrix. The company used its proprietary CXU platform to print scaffolds derived from bovine collagen that are designed to behave like human tissue.
Platform Designed for Personalized Implants
According to Conexeu, the development could pave the way for patient-specific implants for craniofacial, breast, periodontal, and soft-tissue reconstruction. The company said the material supports vascularization, which is considered critical for long-term cell viability in regenerative treatments.
“The ability to print a functional collagen-based extracellular matrix that behaves like the architecture of real tissue, versus synthetic polymers or non-functional collagens, represents a new step for regenerative medicine,” said Dr Claudia Chavez-Munoz, chief science officer of Conexeu. “By showing that CXU can print tissue structures, we are opening the door to truly personalized implants and grafts. Data has shown that CXU is a material that the body recognizes as its own. This could be a game changer in the fields of aesthetics and tissue reconstruction. If, and when, cleared by the FDA, this will place CXU at the forefront of all bioinks, being the first collagen-based extracellular matrix medical grade in the market.”
Dual Use for Clinical and Printing Applications
The CXU material is designed to function both as an injectable regenerative device and as a printable bioink. The company is targeting multiple markets with the platform, including wound care, aesthetics, dental, reconstructive surgery, and 3D bioprinting.
“This breakthrough is a declaration,” said Miles Harrison, president and CEO of Conexeu. “The future of medicine is not just repairing tissue; it is creating it. With CXU, we can inject regeneration today, and we can design regeneration for tomorrow. This is the dawn of personalized tissue on demand. CXU prints with precision but lives like biology and it sets the stage for a completely new era of human reconstruction.”
Clinical Product Advances Toward FDA Submission
The company’s first clinical product, Ten Minute Tissue, is based on the same CXU technology. It remains investigational and has not been cleared by any regulatory agency. Conexeu is planning a pre-510(k) submission in the third quarter of 2026. In pre-clinical studies, the product showed faster wound healing and reduced scarring.
Company Origin and IP Portfolio
Conexeu was founded in 2022 to commercialize technology emerging from academic research into thermosensitive collagen scaffolds. The CXU material remains liquid at room temperature and gels at body temperature. The company holds patents in the United States, European Union, Japan, and Australia, with additional filings pending.
Photo: ID 125378010 © Komgrit Pradissagul | Dreamstime.com
